Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$890.34 USD

890.34
736,214

+5.86 (0.66%)

Updated Oct 2, 2024 12:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Why Is Eli Lilly (LLY) Up 2.7% Since Its Last Earnings Report?

Eli Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis

    Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.

      Amgen's Label Expansion Application for Prolia Gets FDA Nod

      Amgen (AMGN) announces FDA approval for its regulatory application seeking label expansion for Prolia.

        Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod

        Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.

          Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

          Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

            AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down

            AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.

              Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

              Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.

                Roche Tecentriq Combo Achieves Longer Overall Survival Rate

                Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

                  Eli Lilly's Cluster Headache Candidate Succeeds in Phase III

                  Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.

                    Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline

                    Eli Lilly (LLY) to buy an early phase oncology asset, AK-01, from AurKa Pharma to expand its oncology pipeline.

                      Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y

                      Nektar (NKTR) reports wider-than-expected loss in Q1 while revenues rise substantially year over year. It collaborates with Bristol-Myers for advancing immuno-oncology and immunology pipeline.

                        AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

                        AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

                          Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down

                          Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.

                            Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss

                            Radius Health (RDUS) narrower-than-expected loss in the first quarter was encouraging as sales of lead drug Tymlos pick up amid competition.

                              David Borun headshot

                              Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.

                              Bid U.S. drug makers are seen as largely spared the worst in the Trump Administrations plans to control drug prices.

                                AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected

                                AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.

                                  What's in Store for Radius Health (RDUS) in Q1 Earnings?

                                  Investors are expected to focus on the uptake of lead drug, Tymlos, and other pipeline developments when Radius Health (RDUS) reports results for the first quarter.

                                    Sweta Killa headshot

                                    Q1 Earnings Drag Pharma ETFs Down

                                    Pharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space, pushing many funds to 52-week lows.

                                      Top Ranked Growth Stocks to Buy for May 4th

                                      Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, May 4th:

                                        United Therapeutics (UTHR) Q1 Earnings Rise, Sales Drop Q/Q

                                        United Therapeutics' (UTHR) earnings per share rise in the first quarter. Sales drop sequentially due to unfavorable timing of distributor orders. Shares sink almost 7%.

                                          Top Ranked Growth Stocks to Buy for May 2nd

                                          Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, May 2nd:

                                            Top Ranked Growth Stocks to Buy for April 30th

                                            Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 30th:

                                              Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

                                              The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

                                                Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up

                                                Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.

                                                  Kinjel Shah headshot

                                                  Eli Lilly (LLY) Tops Q1 Earnings & Sales, Ups 2018 View

                                                  Eli Lilly (LLY) beat estimates for both earnings and sales in Q1 and raised the guidance for 2018. Shares declined in pre-market trading.